News
QureBio's First Bispecific Antibody Q-1802 Combination Clinical Trial (Phase I/II) Was Approved
Time: 2022-04-12
Source: Viva Biotech
Share:
[Abstract]:The Q-1802 combination is designed to study its preliminary efficacy, safety and tolerability in patients with gastrointestinal tumors.

On April 12, QureBio that invested and incubated by Viva BioInnovator, announced that its self-developed bispecific antibody Q-1802 received a notification of drug clinical trial approval from National Medical Products Administration on April 2, 2022 for Phase I/II clinical trial of preliminary efficacy and safety tolerability in combination with standard therapy in patients with gastrointestinal tumors.

 

Previously, the project has successfully completed the IND application in China and the United States. It has successfully advanced the Phase I clinical study of Q-1802 safety and efficacy exploration. Results of the Phase I partial safety study will be presented at the June 2022 ASCO Annual Meeting.

 

 

Media contact: vivapr@vivabiotech.com
Contact Us